Literature DB >> 2910633

The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance.

F Gengo1, C Gabos, J K Miller.   

Abstract

The time course of diphenhydramine concentrations and effects on both mental performance and subjective feelings of drowsiness were assessed in 15 healthy men. Subjects received single oral doses of diphenhydramine, 50 mg, and placebo in this double-blind crossover study. Diphenhydramine plasma concentrations and central nervous system actions were assessed for 24 hours after each treatment. Cognitive impairment was assessed with an automobile driving simulator and digit symbol substitution scores, whereas drowsiness was self-assessed on a visual analog scale. Diphenhydramine produced significant feelings of drowsiness for up to 6 hours after the dose, whereas significant mental impairment was apparent for only 2 hours. Despite the difference in duration of these effects, drowsiness and mental impairment have parallel slopes when effects are related to diphenhydramine concentrations. These data suggest that although the apparent diphenhydramine concentration thresholds to produce drowsiness are lower (30.4 to 41.5 ng/ml) than those needed to produce mental impairment (58.2 to 74.4 ng/ml), these effects have profiles consistent with their being manifestations of the same pharmacologic effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910633     DOI: 10.1038/clpt.1989.3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial.

Authors:  Joris C Verster; A Marit de Weert; Saskia I R Bijtjes; Mounir Aarab; Armand W A A van Oosterwijck; Erik J E Eijken; Marinus N Verbaten; Edmund R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2003-04-30       Impact factor: 4.530

2.  Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.

Authors:  N Cutler; J Sramek; A Veroff; G Block; L Stauffer; C Lines
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

Review 3.  Effects of antihistamine medications on exercise performance. Implications for sportspeople.

Authors:  L C Montgomery; P A Deuster
Journal:  Sports Med       Date:  1993-03       Impact factor: 11.136

Review 4.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

5.  Bioavailability of Triprolidine as a Single Agent or in Combination With Pseudoephedrine: A Randomized, Open-Label Crossover Study in Healthy Volunteers.

Authors:  Salvatore Febbraro; Tim Shea; Ana Santos Cravo
Journal:  Clin Pharmacol Drug Dev       Date:  2020-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.